-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。目標株価を31ドル引き下げ、79ドルとしました。これは、2026年のEPS予想倍率9倍(従来は10倍)に相当し、OMCの10年平均予想PER12倍を下回る水準です。2026年のEPS予想を11.09ドルから8.75ドルに、2027年のEPS予想を12.53ドルから8.91ドルにそれぞれ引き下げました。これは、計画されている資産売却と顧客口座の損失を反映したものです。第1四半期決算では、予想を上回る顧客口座の損失と計画されている資産売却の影響、そして大幅な金利負担増が明らかになったため、投資判断を「買い」から「中立」に引き下げました。これらの逆風は、コアEBITAマージンが14.1%(+240bps)に改善したにもかかわらず、その効果を十分に相殺しています。 21億ドル規模の自社株買いや、OMCの広告ソリューションを近代化し、新規顧客獲得における競争力を向上させる可能性のあるAI搭載のOmniプラットフォームの存在は認識していますが、これらのプラス要因だけでは、短期的な収益と利益への圧力を相殺するには不十分だと考えています。現在の株価水準では、厳しい成長見通しと統合リスクを考慮すると、過去の水準よりも低い適正な株価倍率で取引されるべきだと考えています。
Related Articles
Telix Says Marketing Authorization Application for Glioma Imaging Candidate Accepted for Review in Europe; Shares Up 3%
Telix Pharmaceuticals (ASX:TLX) said Friday its marketing authorization application filed in Europe for TLX101-Px, its glioma imaging candidate, has been validated and accepted for review, moving into a 210-day active assessment phase.In a statement, the company said it is seeking a broad clinical label, reflective of current clinical practice guidelines, with national marketing authorizations expected to follow shortly after a positive outcome at day 210.The company said it aims to expand patient access to advanced imaging that can distinguish progressive or recurrent glioma from treatment-related changes in both adults and children, with potential for additional future indications.TLX101-Px is also being developed as a patient selection and response assessment tool for Telix's glioblastoma therapy candidate TLX101-Tx, which has been granted orphan drug designation in Europe and the US, per the statement.The phase 3 IPAX-BrIGHT trial of TLX101-Tx in patients with recurrent glioblastoma has started patient dosing internationally and is launching in multiple European countries, the company said.Telix Pharmaceuticals' shares were up 3% in recent Friday trade.
Zozo's Profit Climbs 6% in Fiscal Year 2025
Zozo's (TYO:3092) profit attributable to owners of the parent rose 5.7% to 47.93 billion yen for the fiscal year 2025 from 45.35 billion yen a year earlier.The shopping mall operator's basic earnings per share increased to 54.11 yen from 50.90 yen a year ago, according to a Tokyo bourse filing on Thursday.Net sales climbed 7.2% to 228.37 billion yen for the full year ended March 31 from 213.13 billion yen in the prior year.The company declared a year-end dividend of 20 yen per share, payable from June 11.For the fiscal year 2026, the company expects attributable profit of 49.7 billion yen, EPS of 56.20 yen, and net sales of 241.9 billion yen.Zozo plans to pay interim and year-end dividends of 20 yen per share each for the year, which is higher than the amount in the year-ago period.
EML Payments Says Regulators Extend Date for Implementation of Required Guarantee Structure
EML Payments (ASX:EML) said the Australian Prudential Regulation Authority (APRA) and Reserve Bank of Australia (RBA) agreed to extend the date for implementation of the required authorized deposit-taking institution guarantee structure, subject to EML Payment Solutions showing "satisfactory progress" towards obtaining the guarantee via periodic reporting, according to a Friday Australian bourse filing.EML Payment Solutions is engaging with several domestic and international financial institutions, as well as legal advisors and trustee service providers, to design the required guarantee structure.The regulators had earlier said that they require the firm to obtain a guarantee from an authorized deposit-taking institution in respect of stored value liabilities for certain EML Payment Solutions programs by Thursday.